Drug Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Bioengineering
Mylan Announces Final FDA Approval for Verapamil Hydrochloride Extended-Release Capsules (PM)
August 31st, 2007
Mylan Laboratories Inc. (NYSE:MYL) announced that Mylan Pharmaceuticals Inc. has received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application (ANDA) for Verapamil Hydrochloride (HCl) Extended-release (ER) Capsules (PM), 100 mg, 200 mg and 300 mg. Verapamil HCl ER Capsules (PM) are the generic version of Elan Drug Delivery Inc.'s Verelan(R) PM ER Capsules. Verapamil HCl ER Capsules (PM) had U.S. sales of approximately $58 million for the 12 months ending June 30, 2007, for the same strengths. This product will be shipped immediately. Mylan Laboratories Inc. is a leading pharmaceutical...
Source: Drug Week (2007-08-31)
|
